Phase II Study of Eribulin Mesylate and Trastuzumab for Locally Recurrent or Metastatic HER2-Positive Breast Cancer
CME INFORMATION

OVERVIEW OF ACTIVITY

The annual San Antonio Breast Cancer Symposium (SABCS) is unmatched in its significance with regard to the advancement of breast cancer treatment. This unique conference provides many clinicians and scientists from around the world a forum for discussing critical issues in the prevention and management of breast cancer. Therefore, SABCS is targeted by many members of the clinical research community as the optimal time to unveil new clinical data. This creates an environment in which yearly published results from a plethora of ongoing clinical trials lead to the emergence of new therapeutic agents and changes in the indications for existing treatments across all breast cancer subtypes.

Although SABCS currently offers online access to the vast majority of the poster and plenary presentations from the annual meeting, the absence of expert assessment concerning practical applications may yield confusion among community oncologists who are challenged almost daily to appropriately apply a multitude of scientific findings across diverse tumors. Thus, identification of those data sets with immediate or impending relevance to the delivery of quality breast cancer care, in conjunction with professional commentary to address resultant practice ambiguity, may prove vastly beneficial to those physicians who are unable to make the annual pilgrimage to San Antonio. To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets from the latest SABCS, including expert perspectives on how these new evidence-based concepts can and should be incorporated into on- and off-protocol patient care. This activity will assist medical oncologists, radiation oncologists, breast/general surgeons, nurses and other healthcare professionals in the formulation of optimal clinical management strategies and the timely application of new research findings to best-practice patient care.

LEARNING OBJECTIVES

- Appraise recent clinical research findings from the second interim survival analysis of the CLEOPATRA study and the subset analysis of patients based on age, and apply this information to the treatment of patients with metastatic HER2-positive breast cancer.
- Recall the benefits and risks of combining HER2-targeted antibodies with chemotherapeutic agents for the treatment of HER2-positive advanced breast cancer.
- Understand the association between PI3 kinase mutational status and prognosis in patients with HER2-positive metastatic breast cancer.
- Evaluate the efficacy and safety of adding eribulin mesylate to trastuzumab for patients with HER2-positive advanced breast cancer.
- Compare the toxicity profile of T-DM1 across multiple studies in metastatic HER2-positive breast cancer, and consider this information in the selection of optimal HER2-targeted later-line therapy.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentations, read the commentary, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/5MJCSAABC2013/2/CME.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

José Baselga, MD, PhD
Physician-in-Chief
Memorial Sloan-Kettering Cancer Center
New York, New York
Consulting Agreements: Genentech BioOncology, Novartis Pharmaceuticals Corporation.

Kimberly L Blackwell, MD
Professor of Medicine
Director, Breast Cancer Program
Duke Cancer Institute
Durham, North Carolina
Advisory Committee: Novartis Pharmaceuticals Corporation;
Consulting Agreements: Novartis Pharmaceuticals Corporation, Sandoz; Contracted Research: Celgene Corporation, Genentech BioOncology, Roche Laboratories Inc; Speakers Bureau: Genomic Health Inc.

Edith A Perez, MD
Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research
Chief, Division of Hematology and Oncology
Physician-in-Chief
North Carolina Cancer Hospital
Associate Director for Clinical Research
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
Advisory Committee, Consulting Agreements and Speakers Bureau: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi; Research Support: Genentech BioOncology, GlaxoSmithKline, Sanofi.

Lisa A Carey, MD
Deputy Director at Large, Mayo Clinic Cancer Center
Group Vice Chair, Alliance of Clinical Trials in Oncology
Serene M and Frances C Durling Professor of Medicine
Mayo Clinic
Jacksonville, Florida
EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Eisai Inc, Genentech BioOncology and Genomic Health Inc.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: March 2013
Expiration date: March 2014
The new world of HER2-positive breast cancer

To go directly to slides and commentary for this issue, click here.

Last week I met with the new Physician-in-Chief at Memorial Sloan-Kettering Cancer Center, Dr José Baselga, and after talking a bit about his vision for the future of that preeminent institution we focused on a corner of oncology he has influenced mightily throughout his career, breast cancer research. Not surprisingly, we spent much of our time reviewing anti-HER2 treatment — which has witnessed the FDA approval of 2 new agents in the past 9 months. Dr Baselga got things started by commenting on the Phase III trial he chaired, CLEOPATRA, which clearly demonstrated a substantial boost in efficacy when the HER2 dimerization inhibitor pertuzumab (P) was added to docetaxel and trastuzumab (T) as first-line therapy for metastatic HER2-positive disease. In the trial progression-free survival (PFS) increased from 12.4 to 18.5 months with a similar safety profile, and although the magnitude of this landmark finding surprised many observers, Dr Baselga stated that he fully expected the results based on the substantial antitumor activity seen when P was added to T in patients with disease progression on T in a prior Phase II trial.

We then chatted about the antibody-drug conjugate trastuzumab emtansine (T-DM1) and the EMILIA trial that exploded onto the scene during the ASCO 2012 plenary session, revealing T-DM1’s clear-cut superiority in both efficacy (PFS and overall survival) and tolerability over an established and frequently used regimen (capecitabine/lapatinib) among patients who had previously been treated with T + a taxane. As the agent was just approved 2 weeks before the interview, our conversation took on a different tone, as for the first time I was able to ask an investigator the practical (rather than hypothetical) question of current sequencing of therapy for metastatic HER2-positive disease. Dr Baselga, in commenting on this complex issue that has likely been discussed at every tumor board on the planet, slowly removed his eyeglasses, carefully put them on the desk, thought for a moment and then voiced his perspective, which is similar to
those I have heard recently from Dr Eric Winer and others: “Some people are so excited about T-DM1 that they want to use it first line, but I think this is a time for intellectual calm. Right now, trastuzumab, pertuzumab and a taxane is our standard first-line treatment, with T-DM1 as second line.”

For the record, he and his Memorial colleagues usually choose paclitaxel as a partner for T + P, partially based on the reassuring Phase II data the group reported at San Antonio with this regimen. As I have been known to do, I tried to push Dr Baselga a bit regarding his strong feeling not to use T-DM1 first line and asked him how he would approach an 85-year-old patient with ER-negative, HER2-positive metastatic breast cancer for whom traditional chemotherapy might be out of place. He, however, stuck to his guns, commenting that a short taxane course (with T + P) in many fit, older patients is a well-tolerated life investment that results in a median progression-free interval of 18 months.

Whatever the algorithm is for now, it may very well change in a year or so when the MARIANNE study reports. This crucial Phase III first-line trial compares T + a taxane to T-DM1 alone or with P. Dr Baselga very clearly stated his opposition to the nonprotocol use of T-DM1 combined with P until more trial data become available, and other investigators, including Dr Winer, have done the same.

Of course, many other complex questions remain about the treatment of metastatic HER2-positive breast cancer, and below we review some of the more interesting efforts unveiled in San Antonio that attempt to provide needed answers:

1. More from the CLEOPATRA trial: Overall survival benefit; biomarker analysis; effects in older patients

With 154 deaths in the control group and 113 in the T + P + docetaxel arm, the study has now allowed crossover to P. In terms of biomarkers, according to Dr Baselga, who presented these data in San Antonio, perhaps the key factor moving forward will be the identification of PI3-kinase mutations in approximately 25% of HER2-positive tumors and the potential use of PI3-kinase alpha inhibitors, which are currently being evaluated. Finally, although only 126 patients in CLEOPATRA were older than age 65, the benefit they derived from treatment was similar to what was seen with younger patients.

2. Choice of chemotherapy to combine with T + P

Referred to earlier, a San Antonio report from Memorial demonstrated a 76% 6-month PFS rate in 33 evaluable patients receiving T + P + weekly paclitaxel. No unexpected toxicities were encountered, and this work provides additional strength to the conclusion everyone, including the NCCN, had already reached, namely that paclitaxel is a reasonable agent to combine with T and P. To obtain more real-world perspectives on this issue, an international single-arm study (PERUSE) is now evaluating T + P with 3 different taxanes (paclitaxel, nab paclitaxel and docetaxel).
3. Pooled safety analysis of single-agent T-DM1

These data from 882 patients on 6 clinical trials (including EMILIA) revealed few clinically apparent toxicities but did document transient laboratory abnormalities, such as thrombocytopenia and abnormal liver function tests, in a quarter or more of patients. Overall, treatment discontinuation due to toxicity was observed in only 55 patients (6.2%).

4. Eribulin combined with T

Indefinite anti-HER2 treatment is now a standard part of care for patients with HER2-positive metastatic disease, and as new chemotherapy agents are developed, studies are needed to document whether these are safe and efficacious partners for T. This report of 40 patients demonstrated what most observers expected — efficacy similar to other chemotherapy/T combinations (55% CR + PR) and acceptable tolerability comparable to what has been reported with eribulin alone.

For the next issue of this series we review the many San Antonio papers on genomic markers, including yet another analysis with the 21-gene recurrence score in tumor specimens from a prior randomized adjuvant trial, in this case NSABP-B-28, which evaluated the addition of paclitaxel to AC.

Neil Love, MD
Research To Practice
Miami, Florida
Phase II Study of Eribulin Mesylate and Trastuzumab for Locally Recurrent or Metastatic HER2-Positive Breast Cancer

Presentation discussed in this issue


Slides from a presentation at SABCS 2012 and transcribed comments from recent interviews with Edith A Perez, MD (1/17/13) and Lisa A Carey, MD (1/17/13)

Eribulin Mesylate + Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer: Results from a Phase 2, Multicenter, Single-Arm Study

Vahdat L et al.

Proc SABCS 2012;Abstract P5-20-04.
Background

- Eribulin mesylate is a nontaxane inhibitor of microtubule dynamics of the halichondrin class of antineoplastic drugs.
- The Phase III EMBRACE study demonstrated a survival benefit with eribulin relative to commonly used agents for patients with locally recurrent or metastatic breast cancer (mBC) who previously received at least 2 chemotherapeutic regimens for advanced disease (Lancet 2011;377(9769):914).
  - Median overall survival was significantly improved in women who received eribulin versus treatment of physician's choice.
    - 13.1 mo vs 10.6 mo: HR 0.81, p = 0.041
- **Study objective:** To evaluate the antitumor activity and safety of eribulin mesylate in combination with trastuzumab as first-line therapy for patients with locally recurrent or metastatic HER2-positive breast cancer.


Baseline Characteristics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Eribulin/trastuzumab (n = 40)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age, y</td>
<td>58.1</td>
</tr>
<tr>
<td>Metastatic sites (%)</td>
<td></td>
</tr>
<tr>
<td>Liver</td>
<td>52.5</td>
</tr>
<tr>
<td>Lung</td>
<td>42.5</td>
</tr>
<tr>
<td>Bone</td>
<td>35.0</td>
</tr>
<tr>
<td>ER+ disease (%)</td>
<td>67.5</td>
</tr>
<tr>
<td>Mean time from original diagnosis, y</td>
<td>2.4</td>
</tr>
<tr>
<td>Prior trastuzumab* (%)</td>
<td>40.0</td>
</tr>
<tr>
<td>Prior taxane or anthracycline (%)</td>
<td>50.0</td>
</tr>
</tbody>
</table>

* The majority of these patients received trastuzumab in the (neo)adjuvant setting, and 1 patient received it in the metastatic setting.

Phase II Study Design

As of October 26, 2012, 40 of the 52 planned patients had received at least 1 dose of eribulin (enrollment closed).

<table>
<thead>
<tr>
<th>Eligibility</th>
<th>Eribulin mesylate</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Locally recurrent BC or HER2+ mBC</td>
<td>1.4 mg/m² IV</td>
</tr>
<tr>
<td>• No prior chemotherapy treatment for locally recurrent or metastatic</td>
<td>days 1, 8 q21 days</td>
</tr>
<tr>
<td>HER2+ breast cancer</td>
<td>+</td>
</tr>
<tr>
<td>• One prior HR/endocrine treatment and 1 prior HER2+ treatment allowed</td>
<td>trastuzumab</td>
</tr>
<tr>
<td></td>
<td>Initial dose: 8 mg/kg IV</td>
</tr>
<tr>
<td></td>
<td>Subsequent doses: 6 mg/kg IV day 1, q21 days</td>
</tr>
</tbody>
</table>

**Primary objective:** Objective response rate (ORR)

* Data have not fully matured. Preliminary results are presented.


Best Tumor Responses

<table>
<thead>
<tr>
<th></th>
<th>Eribulin/trastuzumab (n = 40)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Objective response rate</td>
<td>55.0%</td>
</tr>
<tr>
<td>Complete response (CR)</td>
<td>5.0%</td>
</tr>
<tr>
<td>Partial response (PR)</td>
<td>50.0%</td>
</tr>
<tr>
<td>Stable disease (SD)</td>
<td>37.5%</td>
</tr>
<tr>
<td>Progressive disease (PD)</td>
<td>2.5%</td>
</tr>
<tr>
<td>Not evaluable/unknown</td>
<td>5.0%</td>
</tr>
<tr>
<td>Clinical benefit rate (CR/PR/SD)*</td>
<td>62.5%</td>
</tr>
<tr>
<td>Disease control rate (CR/PR/SD)</td>
<td>92.5%</td>
</tr>
</tbody>
</table>

* Of at least 180 days in duration

Secondary Efficacy Outcomes

<table>
<thead>
<tr>
<th></th>
<th>All patients</th>
<th>ER+ patients</th>
<th>ER- patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median PFS (n = 40, 27, 11)</td>
<td>9.2 mo</td>
<td>7.1 mo</td>
<td>13.9 mo</td>
</tr>
<tr>
<td>Median TTR (n = 22, 14, 6)</td>
<td>1.3 mo</td>
<td>1.3 mo</td>
<td>1.3 mo</td>
</tr>
<tr>
<td>Median DOR (n = 22, 14, 6)</td>
<td>6.7 mo</td>
<td>6.5 mo</td>
<td>6.7 mo</td>
</tr>
</tbody>
</table>

PFS = progression-free survival; TTR = time to response; DOR = duration of response


Maximum Percent Change of Tumor Summed Diameters from Baseline for Evaluable Patients (n = 40)

With permission from Vahdat L et al. Proc SABCS 2012; Abstract P5-20-04.
Select Adverse Events (n = 40)

<table>
<thead>
<tr>
<th>Adverse event (AE)</th>
<th>All grades</th>
<th>Grade 3/4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alopecia</td>
<td>82.5%</td>
<td>—</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>60.0%</td>
<td>35.0%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>57.5%</td>
<td>2.5%</td>
</tr>
<tr>
<td>Peripheral neuropathy</td>
<td>47.5%</td>
<td>12.5%</td>
</tr>
<tr>
<td>Anemia</td>
<td>22.5%</td>
<td>2.5%</td>
</tr>
<tr>
<td>Dysgeusia</td>
<td>25.0%</td>
<td>0%</td>
</tr>
<tr>
<td>AE leading to eribulin discontinuation</td>
<td>12.5%</td>
<td></td>
</tr>
<tr>
<td>AE leading to eribulin dose reduction</td>
<td>20.0%</td>
<td></td>
</tr>
</tbody>
</table>


Author Conclusions

- These preliminary results suggest that the combination of eribulin and trastuzumab appears to have considerable activity with an acceptable toxicity profile as first-line therapy for HER2-positive locally advanced or metastatic breast cancer.
- Most commonly observed treatment-related AEs included:
  - Alopecia, fatigue, neutropenia, peripheral neuropathy and nausea
- Most common Grade 3/4 AE was neutropenia.
- This study has completed enrollment, and final results are expected by December 2013.

Investigator Commentary: A Phase II Study of Eribulin Mesylate and Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer

People have been eagerly awaiting these data for some time. Eribulin has single-agent activity in the setting of advanced breast cancer, so I’m not surprised that these investigators demonstrated a high response rate when eribulin was administered in combination with trastuzumab for patients with locally recurrent or metastatic HER2-positive disease.

Interview with Edith A Perez, MD, January 17, 2013

This interim analysis of a Phase II study reported a response rate of more than 50% and a clinical benefit rate of more than 60% with eribulin/trastuzumab. Progression-free survival was also reasonable. A number of dose reductions and delays and a fair amount of discontinuation were reported. Dose reduction or delay was necessary for approximately 1 in 5 patients, but those adjustments appeared to be related to eribulin-based toxicities such as asthenia, peripheral neuropathy and neutropenia. We don’t know whether it’s possible that trastuzumab was “turning up the volume” on those side effects because there was no eribulin-alone arm. It wouldn’t surprise me because with some of the biologic agents an augmentation of what you traditionally consider to be the cytotoxic side effects is apparent.

Interview with Lisa A Carey, MD, January 17, 2013